![[Chart]](http://ichart.europe.yahoo.com/c/0b/s/shp.l)
| | | Address: | Hampshire International Business Park Chineham
Basingstoke/Hamps RG24 8EP United Kingdom | | Web Site: | www.shire.com | | Index: | FTSE100 | STOXX600 | |
Market Place(s)
: | Frankfurt | London | New York | |
Number Of Shares
: | 561,054,000 | | Sector: | Health | | Industry: | Pharmaceuticals | | Sub-Industry: | Pharmaceutical Products |
|
| | Shire Pharmaceuticals Group Plc : treating all sorts of diseases The British Shire Pharmaceuticals Group Plc develops effective drugs that it manufactures itself, to treat a variety of diseases and health disorders - cancer, metabolic disorders, nervous and gastro-enterological disorders (half its products). It makes Carbatrol to treat epilepsy, Adderall to treat hyperactivity and Reminyl for Alzheimer's. Shire Pharmaceuticals Group operates all over the world - in Europe, the USA, Canada, Australia, South Africa and Asia - and has become a vital supplier for sick people, owing to its intensive R&D into developing increasingly innovative drugs. It merged in 2001 with the Canadian group, BioChem Pharma that, in partnership with the global giant, GlaxoSmithKline, has developed treatments for HIV (tri-therapy) and hepatitis B (Zeffix). |
|
| ISIN: | JE00B2QKY057 | | Reuters Code: | SHP.L | |
Local Code
: | SHP | | Auditor: | Deloitte & Touche | | Number of employees: | 2,868 ( 31/12/2006 )
2,403 ( 31/12/2005 ) |
|
| Chairman of Board of Directors: | Dr James Cavanaugh | | Chief Executive Officer: | Matthew Emmens | | Chief Financial Officer: | Angus Russell | | Corporate Secretary: | Tatjana May | | Data as of 31/12/2006. |
|
| Annual report: | 22/02/2010 | | Shareholder ’s meeting: | 28/04/2010 | | Profits 1st half-year: | 24/07/2009 |
|
| Fidelity International Limited: | 5.2% | | Franklin Resources Inc: | 3.9% | | Legal and General Plc: | 3.3% | | Prudential Assurance Company: | 3% |
|
| | |
Year
|
2007
|
2006
|
2005
|
2004
|
2003
| |
Net Operating revenues*
| 2,436.3 | 1,796.5 | 1,599.3 | 1,363.2 | 1,211.6 | |
Net Profit*
| N/A | 56.2 | -410.8 | 269 | 276.05 | | * in million(s) of
Pound
|
|
|
Year
|
2006
|
2005
|
2004
|
2003
| |
Earnings per share*
| 11.2 | -82.1 | 54.2 | 55.4 | | * in
pence |
|
| Sale of pharmaceuticals: | 89% | | Pharmaceuticals licences: | 10% | | Others: | 1% | | Sector Data as of 31/12/2007 |
|
| SALES PER GEOGRAPHIC AREA | |
| Geographic areas | | North America: | 75% | | Rest of the World: | 25% | | Areas data as of 31/12/2006 | | Profile as of 31/12/2006.
Data provided by EuroStockCity |
|
|
|
13.00 (1.12%) 
Profile
